# A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy

> **NCT05276310** · PHASE1 · RECRUITING · sponsor: **ImmuneOncia Therapeutics Inc.** · enrollment: 62 (estimated)

## Conditions studied

- Advanced Cancer

## Interventions

- **BIOLOGICAL:** IMC-002

## Key facts

- **NCT ID:** NCT05276310
- **Lead sponsor:** ImmuneOncia Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-02
- **Primary completion:** 2027-12-17
- **Final completion:** 2029-08-30
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05276310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05276310, "A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05276310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*